WS #12080
Bloomberg reports OpenAI is working on an AI-powered screenless speaker, sending Sonos shares down ~3% after-hours on competitive threat. Celcuity announced FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- breast cancer, reducing risk of progression by 76% in Phase 3 trial.
OpenAI AI Speaker and Sonos Impact
Bloomberg reports OpenAI is working on an AI-powered screenless speaker, sending Sonos shares down ~3% after-hours on competitive threat.
Celcuity announced FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- breast cancer, reducing risk of progression by 76% in Phase 3 trial.